Contact us Find us Register
Back to previous section

Abingdon Health lands £4.8m lateral‑flow diagnostics contracts.

Rapid diagnostic tests business Abingdon Health has been awarded a series of "significant contracts" with a USA-based customer to develop, and scale up to manufacture several multiplex quantitative lateral flow assay systems measuring multiple biomarkers simultaneously in human samples.

  • Abingdon Health
  • 30 March 2026 10:57:12
Abingdon Health

Source: Sharecast

Abingdon said on Monday that the contracts - which include full programme management, the management of regulatory processes, and analytical and clinical performance services - had a total value of approximately £4.8m based on the agreed scope of work and will be delivered over a roughly 27-month period, commencing immediately.

The AIM-listed firm said the contracts would be executed via a series of work packages based on agreed milestones, with potential further scope beyond that period including appointment as legal manufacturer.

"The contracts represent an important validation of Abingdon Health's full programme management CDMO service which offers development from feasibility and initial regulatory pathway provision through to product manufacture and multi-territory regulatory approvals," said Abingdon Health. "It underscores Abingdon Health's position as a leading provider of integrated CDMO/CRO services for rapid diagnostic tests and med-tech."

As of 1055 BST, Abingdon Health shares were up 13.6% at 8.24p.

Reporting by Iain Gilbert at Sharecast.com

See latest RNS at Investegate

N/A

ISIN: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.